Response Biomedical's Q2 Revenues Rise 17 Percent; Heart Assay for New System Fails to Clear FDA | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Diagnostics firm Response Biomedical today said that revenues for the second quarter rose 17 percent as it trimmed its net loss following a reorganization.

It also disclosed in a document filed with the US Securities and Exchange Commission that its heart failure assay was not cleared by the US Food and Drug Administration for marketing on its Ramp 200 system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.